Greycroft announces its investment in Boltz's $110M Series A, a biomolecular AI company whose models predict protein-molecule interactions at AlphaFold3-level accuracy, enabling pharma to shift drug discovery from wet-lab iteration to computational design.
Read the full post on Greycroft.com ↗
Topics: Biotech & Life Sciences · AI Infrastructure
Published by Greycroft.com · their site ↗
SandHill indexes 800+ venture capital blogs and newsletters and sends the best of them every Sunday. Browse the sources · browse by topic · read the blog.
Suggest a blog or newsletter for the SandHill index. We track the RSS feed and feature the best pieces in the weekly digest.
The latest theses & analyses from 800+ venture investors, curated into one email. Join 5,000+ investors, founders and LPs.